updated 5/10/2010 9:27:00 AM ET 2010-05-10T13:27:00

Cypress Bioscience Inc. said Monday its first-quarter loss narrowed on a sharp decline in research and development expenses and higher revenue.

The bulk of its revenue came from Savella, a drug for the pain disorder Fibromylagia. Forest Laboratories markets the drug.

Cypress Bioscience reported a net loss of $4.6 million, or 12 cents per share, compared with a loss of $9.2 million, or 24 cents per share, a year earlier.

Revenue rose to $8.1 million from $7.9 million.

Operating expenses fell 27 percent to $12.9 million, mainly on lower costs research and development costs.

Analysts polled by Thomson Reuters expected a smaller loss of 10 cents on $8.5 million in revenue.

Shares of Cypress Bioscience closed at $4.54 Friday.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com